2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma

BACKGROUND: Both everolimus and axitinib are approved for patients with metastatic renal cell carcinoma (mRCC) in second-line therapy. Currently, there are no comparative clinical trials reported. PURPOSE: The objective of this study is to assess the effectiveness and safety of everolimus vs axitini...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Collado-Borrell, R, Escudero-Vilaplana, V, Ortega-Navarro, C, García-Martín, E, Herranz-Alonso, A, Sanjurjo-Saez, M
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 2: Selection, procurement and distribution
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535217/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.28
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky